Analysis of Clinical Outcomes and Complications in Patients Received Liver Transplantation: A Retrospective Study

Sponsor
China Medical University Hospital (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05587556
Collaborator
(none)
1,400
1
35
40

Study Details

Study Description

Brief Summary

Liver transplantation is the last-line method for liver failure. Thomas Starzl completed the first liver transplant in 1967, liver transplantation is developing rapidly. In Taiwan, the first liver transplantation was started in 1984, and the living donor liver transplantation was started in 1994. According to statistics from the Taiwan Organ Transplant Registration Center, from 2005 to 2018, a total of 6,211 liver transplants were completed in Taiwan, and the three-year survival rate was 78.9%.

The success rate of liver transplantation is closely related to the operation method, complications, the patient's conditions, and postoperative care. Besides, Liver cancer is the sixth most common cancer in the whole world and also the fourth leading cause of cancer-related death. Approximately 90% of patients are diagnosed with liver cirrhosis at the same time when they are diagnosed with liver cancer. Once the late stages of liver cirrhosis happen, the effect of treatment will be reduced. Therefore, liver transplantation is the only treatment option that can solve the simultaneous occurrence of liver cirrhosis and liver cancer. Since 1996, liver transplantation has been used to treat liver cancer, the organ source is always the Achilles tendon of organ transplantation. Therefore, Milan criteria was designed to achieve the justice of organ share. However, living donor liver transplant is more popular in Eastern countries because of religious factors and ethical issues and many famous medical centers are trying to expand the original Milan or UCSF criteria, such as Kyoto criteria and Up-to-7 criteria, hoping to save more patients. However, with the expansion of conditions, the chance of recurrence or metastasis after transplantation is bound to increase. According to reports from different famous medical centers, the recurrence rate of liver cancer after liver transplantation is about 10-20%.

Therefore, we assume that patients with liver replacement caused by different diseases may have other postoperative conditions and complications. This study will review the preoperative diagnosis, surgical status, postoperative status, medication status, complications and recurrence of liver transplant patients in our hospital for statistical analysis.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    1400 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Retrospective
    Official Title:
    Analysis of Clinical Outcomes and Complications in Patients Received Liver Transplantation: A Retrospective Study
    Actual Study Start Date :
    Feb 1, 2022
    Anticipated Primary Completion Date :
    Oct 31, 2024
    Anticipated Study Completion Date :
    Dec 31, 2024

    Outcome Measures

    Primary Outcome Measures

    1. The survial rate of the patients [Jan. 2002 to Dec. 2021]

      To investigate whether preoperative diagnosis, surgical status, postoperative status, medication status, complications and recurrence have significant differences in the survival rate of patients.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • 1400 patients who received liver transplantation or patients who were followed up after liver transplantation
    Exclusion Criteria:
    • Patients who do not meet the inclusion and exclusion criteria

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 China Medical University Hospital Taichung Taiwan

    Sponsors and Collaborators

    • China Medical University Hospital

    Investigators

    • Principal Investigator: Long-Bin Jeng, Organ Transplantation Center, China Medical University Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Long-Bin Jeng, Professor, China Medical University Hospital
    ClinicalTrials.gov Identifier:
    NCT05587556
    Other Study ID Numbers:
    • CMUH110-REC1-235
    First Posted:
    Oct 20, 2022
    Last Update Posted:
    Oct 20, 2022
    Last Verified:
    Jan 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 20, 2022